AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35678800 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg/day orally for 8 weeks)
Number of subjects: 74
Study 35678800 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carboxy-methyl cellulose once daily)
Number of subjects: 74
Study 34259398 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 111
Study 34259398 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 111
Study 34259398 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 111
Study 32111313 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic group (1 mL/L Enrofloxacin 10% in drinking water for 10 days)
Number of subjects: 480
Study 32111313 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulated immune yolk (12.8 g/kg)
Number of subjects: 480
Study 33340376 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish adapted version of the Maslach Burnout Inventory
Number of subjects: 400
Study 33340376 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 400
Study 32232261 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit mastication with 10% extra-virgin olive oil (EVOB)
Number of subjects: 25
Study 32232261 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit mastication with 10% palm oil (PALMB)
Number of subjects: 25
Study 32232261 — intervention group
Group type: COMPARATOR
Intervention: Biscuit mastication with control biscuit (CONB, 0% lipids)
Number of subjects: 25
Study 34658020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine (150 mg in 20 mL saline)
Number of subjects: 59
Study 34658020 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 59
Study 34623242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 40
Study 34623242 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 32680561 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant Information Leaflets (PILs) regarding investigational medicinal products
Number of subjects: 0
Study 35458155 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon fishmeal
Number of subjects: 5
Study 35458155 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 5
Study 35458155 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting serum)
Number of subjects: 5
Study 32649896 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless piezotome crest split (FPCS)
Number of subjects: 1129
Study 32649896 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone block grafting (ABBG)
Number of subjects: 1129
Study 35301810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib 100 mg + Ritonavir 100 mg
Number of subjects: 51
Study 35301810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib 1200 mg
Number of subjects: 51
Study 35301810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib 400 mg + Ritonavir 100 mg
Number of subjects: 51
Study 35301810 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 51
Study 35301810 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 51
Study 35301810 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (therapeutic and supratherapeutic concentrations)
Number of subjects: 51
Study 32450626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg IV or 100 mg SC)
Number of subjects: 0
Study 32450626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (75 mg IV)
Number of subjects: 0
Study 32450626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35601466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 500
Study 35601466 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 500
Study 32271806 — intervention group
Group type: EXPERIMENTAL
Intervention: Draft genome assembly of Sinapis alba with 96x coverage on the Illumina platform, resulting in a genome size of 459 Mbp covered in 403,423 contigs with an average size of 1138.04 bp.
Number of subjects: 0
Study 32271806 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of simple sequence repeat (SSR) markers from the genome assembly, yielding 70731 unique primer pairs.
Number of subjects: 0
Study 32271806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene prediction using AUGUSTUS identified 113,107 probable genes with an average size of 684 bp.
Number of subjects: 0
Study 32271806 — intervention group
Group type: EXPERIMENTAL
Intervention: GO level annotations recorded after BLASTX results.
Number of subjects: 0
Study 32333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Public transportation plus active commuting (IG-PT)
Number of subjects: 73
Study 32333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling group (IG-C)
Number of subjects: 73
Study 32333707 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting to work for 12 months
Number of subjects: 73
Study 32333707 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 73
Study 34418633 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes education
Number of subjects: 901
Study 34418633 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education
Number of subjects: 901
Study 36158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese exercise combined with massage (TCEs plus TCM)
Number of subjects: 272
Study 36158965 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese massage alone (TCM)
Number of subjects: 272
Study 34643679 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT plus RG (n=80)
Number of subjects: 158
Study 34643679 — intervention group
Group type: COMPARATOR
Intervention: FACT as usual (n=78)
Number of subjects: 158
Study 32702760 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (≥ 5 minutes)
Number of subjects: 73
Study 32702760 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (≤ 20 seconds)
Number of subjects: 73
Study 33303928 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HIIE serum (50% autologous serum collected after high intensity interval exercise)
Number of subjects: 8
Study 33303928 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exhaustive exercise serum (50% autologous serum collected after exhaustive exercise)
Number of subjects: 8
Study 35292212 — intervention group
Group type: EXPERIMENTAL
Intervention: IIS training program (2-hour training including online article, demonstration videos, implementation guide, and informational flyer)
Number of subjects: 41
Study 35292212 — intervention group
Group type: EXPERIMENTAL
Intervention: IIS training program
Number of subjects: 41
Study 35292212 — intervention group
Group type: COMPARATOR
Intervention: Control group (informational flyer only)
Number of subjects: 41
Study 34907924 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 70
Study 34907924 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous Electrical Stimulation (TES)
Number of subjects: 70
Study 33992561 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue (AFG)
Number of subjects: 140
Study 33992561 — intervention group
Group type: COMPARATOR
Intervention: Commercial fibrin glue (CFG)
Number of subjects: 140
Study 36214590 — intervention group
Group type: EXPERIMENTAL
Intervention: Single screening colonoscopy invitation (invited group)
Number of subjects: 84585
Study 36214590 — intervention group
Group type: COMPARATOR
Intervention: No invitation or screening (usual-care group)
Number of subjects: 84585
Study 33827433 — intervention group
Group type: COMPARATOR
Intervention: Usual care consultations by GPNs
Number of subjects: 53
Study 34626108 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Program (SCP)
Number of subjects: 48000
Study 34626108 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Medication (SCM)
Number of subjects: 48000
Study 34626108 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP completion and SCM use
Number of subjects: 48000
Study 34626108 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP
Number of subjects: 48000
Study 34626108 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM
Number of subjects: 48000
Study 32225267 — intervention group
Group type: EXPERIMENTAL
Intervention: Mueller matrix images analysis
Number of subjects: 0
Study 32225267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier spectra of first and fourth row elements
Number of subjects: 0
Study 32225267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier spectra of every MM element
Number of subjects: 0
Study 32225267 — intervention group
Group type: EXPERIMENTAL
Intervention: M31 element analysis
Number of subjects: 0
Study 36164138 — intervention group
Group type: COMPARATOR
Intervention: IV Isatuximab (10 mg/kg)
Number of subjects: 56
Study 36164138 — intervention group
Group type: COMPARATOR
Intervention: SC Isatuximab (1000 mg)
Number of subjects: 56
Study 36164138 — intervention group
Group type: COMPARATOR
Intervention: SC Isatuximab (1400 mg)
Number of subjects: 56
Study 36164138 — intervention group
Group type: EXPERIMENTAL
Intervention: OBDS Isatuximab (1400 mg)
Number of subjects: 56
Study 36164138 — intervention group
Group type: EXPERIMENTAL
Intervention: SC Isatuximab (1400 mg) + OBDS
Number of subjects: 56
Study 34689519 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 63
Study 34689519 — intervention group
Group type: COMPARATOR
Intervention: Control (dietary guidance only)
Number of subjects: 63
Study 32578755 — intervention group
Group type: EXPERIMENTAL
Intervention: Classes with active participation of students, skills training, and clinical simulation
Number of subjects: 34
Study 32578755 — intervention group
Group type: COMPARATOR
Intervention: Classes with active participation of students and skills training
Number of subjects: 34
Study 35902188 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised GP‐initiated phone call
Number of subjects: 1834
Study 35902188 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1834
Study 33739218 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 118
Study 32150514 — intervention group
Group type: EXPERIMENTAL
Intervention: MapMyFitness smartphone application and Facebook-delivered health education intervention
Number of subjects: 44
Study 32150514 — intervention group
Group type: COMPARATOR
Intervention: Facebook-delivered health education intervention (comparison group)
Number of subjects: 44
Study 34284167 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT electrical stimulation during working memory task trials
Number of subjects: 0
Study 34284167 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT electrical stimulation
Number of subjects: 0
Study 34284167 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased gamma power during pre-stimulus and retrieval period
Number of subjects: 0
Study 35668633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) variability
Number of subjects: 2400
Study 35668633 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride variability
Number of subjects: 2400
Study 35668633 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) variability
Number of subjects: 2400
Study 35668633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL) variability
Number of subjects: 2400
Study 35668633 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in other lipids
Number of subjects: 2400
Study 34645532 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-CPR
Number of subjects: 100
Study 34645532 — intervention group
Group type: COMPARATOR
Intervention: U-CPR
Number of subjects: 100
Study 35275091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 76
Study 35275091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 33187891 — intervention group
Group type: EXPERIMENTAL
Intervention: C0–C2 axial rotation test
Number of subjects: 70
Study 33187891 — intervention group
Group type: EXPERIMENTAL
Intervention: C0–C2 axial rotation test in subjects with CGH
Number of subjects: 70
Study 33187891 — intervention group
Group type: EXPERIMENTAL
Intervention: C0–C2 axial rotation test in patients with episodic migraine
Number of subjects: 70
Study 35644958 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial canthus peribulbar block (PB)
Number of subjects: 60
Study 35644958 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study 32540634 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of standardized ashwagandha extract (Shoden®) once daily for six weeks
Number of subjects: 150
Study 32540634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 35793512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal exercises (Group A)
Number of subjects: 56
Study 35793512 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial exercises (Group B)
Number of subjects: 56
Study 33096225 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Fitness Buddy Ecosystem (VFB)
Number of subjects: 24
Study 33096225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual pet)
Number of subjects: 24
Study 35809401 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive human milk diet (human milk formula and human milk derived fortifier)
Number of subjects: 38
Study 35809401 — intervention group
Group type: COMPARATOR
Intervention: Cow milk-based supplementation (preterm formula and cow milk-based fortifier)
Number of subjects: 38
Study 33966330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast blood loss simulation
Number of subjects: 21
Study 33966330 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow blood loss simulation
Number of subjects: 21
Study 34762533 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM before & after pain stimulation
Number of subjects: 10
Study 34762533 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM before pain stimulation
Number of subjects: 10
Study 34762533 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM after pain stimulation
Number of subjects: 10
Study 34762533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34217572 — intervention group
Group type: COMPARATOR
Intervention: Standard dose-interval (2 weeks)
Number of subjects: 156
Study 34217572 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dose-interval (6 months)
Number of subjects: 156
Study 34217572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dose-intervals
Number of subjects: 156
Study 33636416 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma ET-1 levels
Number of subjects: 210
Study 33636416 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in ET-1 levels over 24 weeks
Number of subjects: 210
Study 33636416 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ET-1 levels
Number of subjects: 210
Study 34579149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention including dietary assessment, individual feedback, and dietary guidance
Number of subjects: 194
Study 34579149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 194
Study 34579149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 36198461 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (TT) + Long pulse width stimulation (LPWS)
Number of subjects: 24
Study 36198461 — intervention group
Group type: COMPARATOR
Intervention: Testosterone treatment (TT) + neuromuscular electrical stimulation via telehealth
Number of subjects: 24
Study 34591518 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive message about individuals who use PBS
Number of subjects: 147
Study 34591518 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative message about individuals who do not use PBS
Number of subjects: 147
Study 34591518 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only control group
Number of subjects: 147
Study 35217515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with 24 Gray epimacular brachytherapy (EMB) and pro re nata (PRN) ranibizumab, n=224
Number of subjects: 363
Study 35217515 — intervention group
Group type: COMPARATOR
Intervention: PRN ranibizumab monotherapy, n=119
Number of subjects: 363
Study 35217515 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB group
Number of subjects: 363
Study 35217515 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab group
Number of subjects: 363
Study 35217515 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB group (participants with microvascular abnormalities at month 24)
Number of subjects: 363
Study 35217515 — intervention group
Group type: EXPERIMENTAL
Intervention: EMB group (participants without microvascular abnormalities at month 24)
Number of subjects: 363
Study 32565105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dart-throwing motion (DTM) plane exercise
Number of subjects: 24
Study 32701508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 0
Study 32701508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35037813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 485
Study 33449396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water (0.2 mL)
Number of subjects: 30
Study 33449396 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (58.5 mg/mL; active control)
Number of subjects: 30
Study 33449396 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9 mg/mL; passive control)
Number of subjects: 30
Study 33449396 — intervention group
Group type: COMPARATOR
Intervention: All substances
Number of subjects: 30
Study 32080074 — intervention group
Group type: EXPERIMENTAL
Intervention: Phellinus linteus (PL) 1,000 mg
Number of subjects: 24
Study 32080074 — intervention group
Group type: EXPERIMENTAL
Intervention: Phellinus linteus (PL) 1,500 mg
Number of subjects: 24
Study 32080074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 35796831 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mindfulness-based stress reduction (MBSR) program
Number of subjects: 50
Study 35796831 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 33653745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool HABIT-ILE
Number of subjects: 60
Study 33653745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 35809255 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐R electric rechargeable toothbrush (Oral‐B iO with Oral‐B Gentle Care brush head)
Number of subjects: 100
Study 35809255 — intervention group
Group type: COMPARATOR
Intervention: Soft manual toothbrush (Oral‐B Indicator)
Number of subjects: 100
Study 33998155 — intervention group
Group type: COMPARATOR
Intervention: Introducer needle (Group “I”)
Number of subjects: 426
Study 33998155 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring‐loaded pneumoperitoneum (Veress) needle (Group “V”)
Number of subjects: 426
Study 33413217 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk group
Number of subjects: 1600
Study 33413217 — intervention group
Group type: COMPARATOR
Intervention: Low genetic risk group
Number of subjects: 1600
Study 32034403 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) high in dietary fiber, whole grain, intrinsic sugars, and starch for 26 weeks
Number of subjects: 62
Study 35022317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric fatty supplement (HCFS; 405 kcal/day, 100% fat)
Number of subjects: 64
Study 35022317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-caloric fatty supplement (UHCFS; 810 kcal/day, 100% fat)
Number of subjects: 64
Study 35022317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-caloric, carbohydrate-rich supplement (UHCCS; 900 kcal/day, 49% carbohydrates)
Number of subjects: 64
Study 35022317 — intervention group
Group type: COMPARATOR
Intervention: Open control (OC) group without any supplement
Number of subjects: 64
Study 33199226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine perfusion
Number of subjects: 24
Study 33199226 — intervention group
Group type: COMPARATOR
Intervention: Saline perfusion (Control)
Number of subjects: 24
Study 33048923 — intervention group
Group type: EXPERIMENTAL
Intervention: SMASH intervention (pharmacist-led Safety Medication dASHboard)
Number of subjects: 47413
Study 32997348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-specific mindful attention training
Number of subjects: 60
Study 32997348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific mindful attention training
Number of subjects: 60
Study 32997348 — intervention group
Group type: COMPARATOR
Intervention: No mindful attention training
Number of subjects: 60
Study 35246099 — intervention group
Group type: EXPERIMENTAL
Intervention: Live your life without diabetes intervention
Number of subjects: 127
Study 35246099 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 127
Study 33407710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 0
Study 33407710 — intervention group
Group type: COMPARATOR
Intervention: Intervention B
Number of subjects: 0
Study 34311747 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical intervention group
Number of subjects: 160
Study 34311747 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention group
Number of subjects: 160
Study 34311747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention group (both biomechanical and psychosocial intervention)
Number of subjects: 160
Study 34311747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 33228496 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care
Number of subjects: 80
Study 35973788 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from dermatological nurses
Number of subjects: 103
Study 35973788 — intervention group
Group type: COMPARATOR
Intervention: Standard care without nurse support
Number of subjects: 103